Dr Neha Issar-Brown is Chief Executive Officer of the British Pharmacological Society and Managing Director of BPS Assessment, the Society’s prescribing skills learning and assessment arm. With more than two decades’ experience across health, science, innovation and policy, Neha has held senior leadership roles across the public, charitable and private sectors, including at UK Research and Innovation (UKRI), the Medical Research Council (MRC), Fight for Sight, Arthritis UK and the Royal Society. She began her scientific career internationally, completing doctoral and postdoctoral research at the Institut Pasteur and INSERM in France, and the University of Heidelberg in Germany. Neha also serves as a Non-Executive Director, board chair, advisor and trustee across the NHS, arts and education sectors, bringing expertise in strategy, governance, quality, equity and system-wide improvement. At the British Pharmacological Society, Neha leads work to advance pharmacological science, strengthen professional capability and build partnerships that support evidence-informed solutions to improve health outcomes globally.

Jennifer Martin is a general physician and clinical pharmacologist in Newcastle Australia. She has been clinical pharmacology editor for a number of Journals over the last few decades including MJA and IMJ, and 10 years as a Reviewing Editor for BJCP before becoming Deputy Editor then Editor-in-Chief of PR&P. She is also the lead clinical pharmacologist for NSW Health managing the State Formulary amongst other roles and a keen pharmacology teacher researcher and educator.

Péter Ferdinandy received Medical Doctor (MD) degree in 1991, a PhD in 1995 at the University of Szeged, Hungary. He had a postdoctoral training at the University of Alberta, Edmonton, Canada (1997-1999). He became a registered clinical pharmacologist in 1999. He received Masters of Business Administration (MBA) diploma in finance and quality management in 2004 from the Budapest University of Technology and Economics. He founded Pharmahungary Group (www.pharmahungary.com), a group of R&D companies in 2001 that have been involved in more than 350 drug and medical device development projects. He was the president of the International Society for Heart Research, European Section, and the chair of the Working Group of Cellular Biology of the Heart of the European Society for Cardiology. He is the past-president of the Hungarian Society of Experimental and Clinical Pharmacology. From Jan 1, 2023, he serves as the Editor in Chief of the British Journal of Pharmacology, a leading international journal in the field of pharmacology and toxicology. He is the vice-rector for science and innovations at Semmelweis University (www.semmelweis.hu), a leading medical science university in Central-Eastern Europe (US News field ranking in Cardiac and Cardiovascular sciences 35th; Shanghai Ranking - top 75 in Pharmacy and Pharmaceutical Sciences; THE world university ranking - top 300). He is also the director of the Department of Pharmacology and Pharmacotherapy at Semmelweis University (www.semmelweis.hu/pharmacology). He published more than 400 papers, received close to 30k citations, and has an H-index of 90 (Google Scholar). He is inventor on 6 patent families. Prof. Ferdinandy has been recognized as Highly Cited Researcher for 7 times (2024, 2017, 2020-2024) acknowledging the world’s most influential scientists.

Geert Jan Groeneveld is Chief Executive Officer of the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands, and Professor of Clinical Neuropharmacology at Leiden University Medical Center (LUMC). He also practices as a neurologist at the LUMC, specialising in patients with neurological causes of chronic pain. He trained in neurology at the University Medical Center Utrecht, where he obtained his PhD on novel pharmacotherapeutic strategies for amyotrophic lateral sclerosis. His career includes experience in industry at Genzyme, where he contributed to gene therapy programmes for Parkinson’s disease and the registration of enzyme replacement therapy for late-onset Pompe disease. He later served as Research Director at CHDR, leading research in neurology and pain. Professor Groeneveld’s work focuses on early-phase clinical drug development for neurological disorders and pain. He has authored over 150 peer-reviewed publications, is actively involved in PhD training, and serves as a senior editor on the editorial board of BJCP.